SV Health Investors’s KalVista Pharmaceuticals KALV Stock Holding History

SV Health Investors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,719,576	Closed	-$25.7M	–	10
2020 Q4	$25.7M	Hold	1,719,576	–	–	12.37%	4
2020 Q3	$21.6M	Hold	1,719,576	–	–	10.97%	4
2020 Q2	$20.8M	Hold	1,719,576	–	–	14.43%	5
2020 Q1	$13.2M	Hold	1,719,576	–	–	11.03%	6
2019 Q4	$30.6M	Hold	1,719,576	–	–	18.55%	2
2019 Q3	$19.9M	Hold	1,719,576	–	–	14.01%	4
2019 Q2	$38.1M	Sell	1,719,576 -111,972	-6%	-$2.63M	25.57%	1
2019 Q1	$52.4M	Sell	1,831,548 -716,654	-28%	-$15.5M	30.75%	1
2018 Q4	$50.3M	Sell	2,548,202 -31,288	-1%	-$629K	30.98%	1
2018 Q3	$57M	Hold	2,579,490	–	–	16.7%	3
2018 Q2	$20.9M	Hold	2,579,490	–	–	9.62%	4
2018 Q1	$24.5M	Hold	2,579,490	–	–	18.34%	3
2017 Q4	$25.1M	Hold	2,579,490	–	–	13.28%	3
2017 Q3	$17.4M	Hold	2,579,490	–	–	13.16%	3
2017 Q2	$19M	Hold	2,579,490	–	–	20.43%	2
2017 Q1	$20.1M	Hold	2,579,490	–	–	22.25%	2
2016 Q4	$18.2M	Buy	+2,579,490	New	+$19M	15.36%	2

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

SV Health Investors's KALV Position: Q1 2021 in Review

SV Health Investors sold out of KalVista Pharmaceuticals (KALV) in Q1 2021, closing a stake of 1,719,576 shares — an estimated $25.7M sold.

SV Health Investors first reported a position in KALV in Q4 2016 and held it in 17 quarters. The position peaked at $57M in Q3 2018. 117 funds tracked by Wall St. Rank hold KALV as of Q1 2021.

SV Health Investors reported no remaining KalVista Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
SV Health Investors sold 1,719,576 KalVista Pharmaceuticals shares in Q1 2021, an estimated $25.7M.
SV Health Investors first reported a position in KalVista Pharmaceuticals in Q4 2016 and held it in 17 quarters.
SV Health Investors's KalVista Pharmaceuticals position peaked at $57M in Q3 2018.
117 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2021.

Based on SV Health Investors's 13F filing for Q1 2021, filed 17 May 2021.